CANDEL THERAPEUTICS I
5.0900
07-November-24 14:59:58
15 minutes delayed
Stocks
-0.2400
-4.50%
Today's range
5.0700 - 5.3600
ISIN
N/A
Source
NASDAQ
-
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
13 Feb 2024 06:30:00 By Nasdaq GlobeNewswire
-
05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
-
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
12 Dec 2023 07:00:01 By Nasdaq GlobeNewswire
-
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
09 Nov 2023 07:00:01 By Nasdaq GlobeNewswire
-
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
04 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
-
03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire
-
18 Oct 2023 10:00:00 By Nasdaq GlobeNewswire
-
27 Sep 2023 08:40:53 By Nasdaq GlobeNewswire
-
26 Sep 2023 07:00:01 By Nasdaq GlobeNewswire
-
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire
-
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
10 Aug 2023 07:00:01 By Nasdaq GlobeNewswire
-
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
02 Aug 2023 07:00:29 By Nasdaq GlobeNewswire
-
13 Jun 2023 07:00:01 By Nasdaq GlobeNewswire
-
08 Jun 2023 07:00:00 By Nasdaq GlobeNewswire
-
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire
-
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
11 May 2023 07:00:01 By Nasdaq GlobeNewswire
-
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
02 May 2023 07:00:01 By Nasdaq GlobeNewswire
-
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
17 Apr 2023 07:00:00 By Nasdaq GlobeNewswire